Surveilling Effluent Water for Epidemic Response Act or the SEWER ActThis bill provides statutory authority for the Centers for Disease Control and Prevention (CDC) National Wastewater Surveillance System (NWSS) program, which detects and monitors pathogens in wastewater. It requires the CDC to expand and intensify the activities of the NWSS, including with respect to SARS-CoV-2 (the virus that causes COVID-19), influenza, mpox, dengue, West Nile virus, and respiratory syncytial virus (RSV). The NWSS provides funding and guidance to public health departments for wastewater surveillance activities. Under the NWSS, health departments and other partners coordinate on wastewater surveillance at sampling sites and share data with the CDC. The NWSS was initially implemented to monitor SARS-CoV-2 and has since expanded to include influenza A, avian influenza A, mpox, and RSV.     

Protecting Resources Of Taxpayers to Eliminate Childhood Transgender Surgeries Act of 2025 or the PROTECTS Act of 2025This bill prohibits providing or using federal funds to perform, refer for, or reimburse any entity for certain gender transition procedures for an individual under the age of 18. The bill’s prohibition applies to certain gender transition procedures that are performed to intentionally change an individual’s body to no longer correspond to the individual's biological sex, including surgeries, medications, and implants specified in the bill. The bill provides exceptions for specified procedures, such as treating certain genetic abnormalities or preventing imminent death or impairment of a major bodily function, when performed by a health care provider with the consent of the individual’s parent or legal guardian. 

Second Chance for Moms Act

Stop Sexually Violent Predators Act

FLASH Act of 2025 Fast-Track Logistics for Acquiring Supplies in a Hurry Act of 2025

Barriers and Regulatory Obstacles Avoids Deployment of Broadband Access and Needs Deregulatory Leadership Act or the BROADBAND Leadership ActThis bill limits the authority of a state or locality to regulate the placement, construction, or modification of telecommunications service facilities.States and localities may not discriminate in such regulations among providers of telecommunications services, including based on the technology used to provide services. In addition, states and localities may not regulate in a manner that effectively prohibits the provision or improvement of interstate or intrastate telecommunications services.However, states and localities may charge reasonable, cost-based fees (1) to review requests to place, construct, or modify telecommunications service facilities; or (2) for the use of property owned or managed by the state or locality for the placement, construction, or modification of those facilities.States or localities must respond to requests to place, construct, or modify facilities and for other related actions by specified deadlines. Such deadlines may only be tolled by a mutual agreement between the applicant and the state or locality, or in the event that the application is incomplete and requires a supplemental submission. If a decision is not made by the deadline, the request is deemed to be approved. Further, denials of requests must be made in writing, supported by evidence, and promptly released to the public.A person adversely affected by an alleged violation of these provisions may petition the courts for expedited review of the actions of the state or locality. 

Health Care Prices Revealed and Information to Consumers Explained Transparency Act or the Health Care PRICE Transparency Act This bill provides statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. Specifically, hospitals must publish in their list of standard charges certain rates negotiated with insurers, discounts for cash payments, and billing codes. Further, hospitals generally must publish the standard charges for the services provided by the hospital that may be scheduled in advance. Additionally, insurance plans must publish the in-network and out-of-network charges for covered items and services and the negotiated prices for covered prescription drugs. Plans must provide a tool for consumers to search for this cost information. Consumers also may request additional information about the costs of specific items or services under their plans.

Daylight ActThis bill allows states to observe daylight saving time year-round. (States may already choose to observe standard time year-round.)

This joint resolution nullifies the final rule titled Energy Conservation Program: Energy Conservation Standards for Commercial Water Heating Equipment, which was submitted by the Department of Energy on October 6, 2023. The rule adopts more stringent energy conservation standards for commercial water heating equipment under the Energy Policy and Conservation Act in order to achieve more energy savings.

Defund Planned Parenthood Act of 2025

Nuclear Waste Informed Consent ActThis bill prohibits the Department of Energy (DOE) from using the Nuclear Waste Fund for certain activities related to radioactive waste disposal unless DOE has entered into a written agreement for a repository with (1) the governor of the state in which the proposed repository will be located, (2) affected local governments, (3) local governments contiguous to the affected local governments if spent nuclear fuel or high-level radioactive waste will be transported through them for disposal at the repository, and (4) affected Indian tribes.

Rural ER Access Act

Expressing support for the designation of January 30, 2025, as CTE (chronic traumatic encephalopathy) and RHI (repeated head impacts) Awareness Day.

America First Act

The HCT/P Modernization Act of 2025This bill requires the Food and Drug Administration (FDA) to provide information to stakeholders and report on the regulation of human cell and tissue products, also referred to as human cells, tissues, or cellular or tissue-based products (HCT/Ps), which are articles containing or consisting of human cells or tissues that are intended for use in a human recipient.The bill requires the FDA to conduct workshops to educate stakeholders and facilitate discussion with them on advancing the science and regulation of human cell and tissue products. The FDA must establish a public docket to receive written comments on this topic, and submit to Congress a report with recommendations on regulating these products. Additionally, the bill requires the FDA to publish on its website educational materials about the Tissue Reference Group and best practices for obtaining a recommendation about products from them. Also, annually for three years, the FDA must publish on its website information on the inquiries submitted and average response times for the Tissue Reference Group, as well as the number of human cell and tissue manufacturers that have registered with the FDA and the number of inspections the FDA has conducted with respect to these manufacturers since 2019. (The Tissue Reference Group is a working group within the FDA that receives product-specific questions from, and provides recommendations for, stakeholders on the regulation of human cell and tissue products under the FDA’s rules.)